Skip to content
Taxonomy
Evolution: CMTA Board Welcomes Coulie & Marks
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth Read More
Leading the Way: The CMTA Invests More Than $200K in Cutting-Edge CMT1A Organoid Research
The CMTA’s new $200K+ investment accelerates CMT1A organoid research, revolutionizing Read More
The CMTA Mourns the Loss of Scientific Advisory Board Member and Esteemed CMT Clinical Researcher
It is with the heaviest of hearts that the Charcot-Marie-Tooth Read More
CMT2S Breakthrough
In a recent announcement, Vanda Pharmaceuticals Inc. shared that the Read More
CMTA Alliance Partner, Applied Therapeutics, Announces Positive 12-Month Results in its Ongoing INSPIRE Phase III Trial for CMT-SORD
In a statement released on February 15, 2024, by Charcot-Marie-Tooth Read More
The CMTA Appoints Professor Charlotte Sumner, M.D., to its Scientific Advisory Board
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth Read More
CMTA Awards Over Half a Million Dollars to Fuel Research in Demyelinating Forms of CMT
Multisite and multiyear collaborative project led by a team of Read More
2023 CMTA-STAR Celebrating our Collective Achievements
Significant Research Investment Made in 2023: We are excited to Read More
ToolGen CMT1A Treatment Receives Orphan Drug Designation
CMTA Alliance Partner ToolGen announced December 18, 2023 that it Read More
Pharnext Announces Disappointing Results for CMT1A Drug Trial PXT-3003
Published: December 11, 2023 French biopharmaceutical company Pharnext SA announced Read More
